Form 4: Gossamer Bio COO/CFO Bryan Giraudo Reports Stock Option Grant

Bryan Giraudo, COO/CFO of Gossamer Bio, Inc., reports the acquisition of stock options for 638,000 shares of common stock on March 4, 2025.

Summary

• On March 4, 2025, Bryan Giraudo, the COO/CFO of Gossamer Bio, Inc., was granted stock options to purchase 638,000 shares of the company's common stock.
• The exercise price of the stock options is $1.13 per share.
• The options vest over a four-year period, with 25% vesting on March 4, 2026, and the remaining 75% vesting monthly thereafter, contingent upon continuous service to the Issuer.
• The options expire on March 3, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options to a key executive like the COO/CFO can align their interests with those of the shareholders, incentivizing them to improve company performance.

Future Outlook

The vesting schedule of the options suggests a long-term commitment from the executive to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. This is a standard practice to incentivize key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options as part of their compensation strategy to align executive incentives with shareholder value.
• The vesting schedule and exercise price are within the typical range for similar grants in comparable companies.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO/CFO to work towards increasing shareholder value.
• Employees may see this as a positive sign, indicating the company's commitment to retaining key personnel.

Key Dates